Pluri (NASDAQ:PLUR) & Gilead Sciences (NASDAQ:GILD) Head to Head Analysis

Gilead Sciences (NASDAQ:GILD) and Pluri (NASDAQ:PLUR) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, valuation, risk, analyst recommendations, institutional ownership, earnings and profitability.

Valuation and Earnings

This table compares Gilead Sciences and Pluri”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gilead Sciences	$28.30 billion	4.03	$5.67 billion	$0.09	1,015.67
Pluri	$598,000.00	40.25	-$20.89 million	($6.03)	-0.72

Gilead Sciences has higher revenue and earnings than Pluri. Pluri is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Gilead Sciences and Pluri’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Gilead Sciences	0.45%	29.00%	9.83%
Pluri	-4,184.28%	-917.18%	-82.85%

Insider & Institutional Ownership

83.7% of Gilead Sciences shares are held by institutional investors. Comparatively, 16.6% of Pluri shares are held by institutional investors. 0.2% of Gilead Sciences shares are held by insiders. Comparatively, 10.2% of Pluri shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Volatility & Risk

Gilead Sciences has a beta of 0.18, meaning that its share price is 82% less volatile than the S&P 500. Comparatively, Pluri has a beta of 1.64, meaning that its share price is 64% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Gilead Sciences and Pluri, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gilead Sciences	0	12	12	3	2.67
Pluri	0	0	0	0	0.00

Gilead Sciences presently has a consensus price target of $96.43, indicating a potential upside of 5.50%. Given Gilead Sciences’ stronger consensus rating and higher probable upside, research analysts clearly believe Gilead Sciences is more favorable than Pluri.

Summary

Gilead Sciences beats Pluri on 12 of the 15 factors compared between the two stocks.

About Gilead Sciences

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.

About Pluri

Pluri Inc., a biotechnology company, engages in the development of placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions. It operates in the field of regenerative medicine, food-tech, and biologics and focuses on establishing partnerships that leverage its 3D cell-based technology to additional industries that require mass cell production. The company's development pipeline includes PLX-PAD, is composed of maternal mesenchymal stromal cells originating from the placenta that is currently under phase III study for orthopedic, phase II study for COVID-19, and phase I/II clinical study for Steroid-Refractory cGVHD indications; and PLX-R18, is composed of fetal MSC like cells originating from the placenta that is currently under phase I study for HCT and pilot study for ARS indications. It is also involved in the development of modified PLX cells. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.